Bristol's Orencia holds potential for juvenile arthritis

07/15/2008 | Yahoo!

Bristol-Myers Squibb Co.'s Orencia reduced flare-ups in children with rheumatoid arthritis by a third compared with those who took placebo, an Italian study found. Researchers said the drug can help pediatric patients who do not respond to an older medication, methotrexate, or tumor necrosis factor blockers, which include Johnson & Johnson's Remicade and Abbott Laboratories' Humira.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA